首页> 外文OA文献 >Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma

【2h】

Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma

机译：通过复发/难治性Hodgkin淋巴瘤影响未选择的自体淋巴细胞再生中未选择的自体淋巴细胞的移植后固结免疫疗法的可行性和功效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Fabio Guolo; Paola Minetto; Filippo Ballerini; Filippo Antonio Canale; Michela Frello; Elisa Coviello; Lorenzo Manconi; Annalisa Kunkl; Elisabetta Tedone; Rosa Mangerini; Paola Contini; Daniela Fenoglio; Maurizio Miglino; Alessandra Bo; Maria Carla De Luigi; Maria Rosaria Ruzzenenti; Paolo Carlier; Alberto Serio; Silvia Luchetti; Emanuela Marcenaro; Paolo Strada; Jean Louis Ravetti; Marco Gobbi; Roberto Massimo Lemoli;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma [J] . Guolo Fabio, Minetto Paola, Ballerini Filippo, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：通过复发/难治性Hodgkin淋巴瘤影响未选择性自体淋巴细胞的未选择性自体淋巴细胞的移植后固结免疫疗法的可行性和有效性
2. Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study [J] . Amraee A., Evazi M. R., Shakeri M., Clinical & translational oncology : . 2019,第8期

机译：Nivolumab作为检查点抑制剂药物对复发/难治古典霍奇金淋巴瘤患者存活率的疗效：前瞻性临床研究的荟萃分析
3. Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse [J] . Robert W. Chen Clinical advances in hematology & oncology: H&O . 2016,第2Suppla1期

机译：在具有高复发风险的霍奇金淋巴瘤患者中，自体干细胞移植（ASCT）后，通过与以布伦妥昔单抗Vedotin合并的AETHERA试验更新的疗效和安全性数据
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure [O] . Kirill V. Lepik, Natalia B. Mikhailova, Elena V. Kondakova, 2020

机译：尼古鲁单抗治疗后复发/难治性霍奇金淋巴瘤患者尼古鲁单抗和苯达莫司汀（NB）的安全性和有效性研究
6. Faculty Opinions recommendation of Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. [O] . David Teachey 2021

机译：作者：王莹，王莹，王莹，王莹，王莹，王莹，王莹，王莹，王莹，王莹，王莹

Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma

著录项

相似文献

相关主题

期刊订阅